Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IDE034

Bispecific antibody · Cytotoxic, directed at B7-H3 (CD276) and PTK7 · developed by IDEAYA Biosciences

Phase 1 Most advanced trial
IDYA Developer
1 Registered trials

What is IDE034?

IDE034 is an antibody-drug conjugate built from a bispecific antibody that binds B7-H3 and PTK7, two antigens co-expressed on certain tumor cells, linked to a topoisomerase I inhibitor payload. The payload is released after internalization and inhibits DNA topoisomerase I, leading to cell cycle arrest and apoptosis. It is studied in multiple solid tumors, including esophageal, ovarian, head and neck, colorectal, prostate, lung, endometrial and triple negative breast cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
B7-H3 (CD276), PTK7
Mechanism
Cytotoxic, directed at B7-H3 (CD276) and PTK7
Pathways
DNA replication inhibition, cell cycle arrest, apoptosis
Therapy area
Oncology
Developer
IDEAYA Biosciences (IDYA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07503808 Phase 1 Esophageal Squamous Cell Carcinoma Recruiting IDYA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Castration-resistant Prostate CancerColorectal CancerEndometrium CancerEsophageal Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaHigh Grade Serous Ovarian CancerNon Small Cell Lung CancerTriple Negative Breast Cancer

Other drugs acting on CD276 / PTK7

More from IDEAYA Biosciences

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the IDYA page.

Follow IDYA, the company behind IDE034

See IDYA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IDYA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.